A statement released earlier today by First Analysis about NeoPharm Inc. (NYSE:NEO) bumps the target price to $11.00
- Updated: October 3, 2016
Stating a potential upside of 0.36%, First Analysis upped the price target of NeoPharm Inc. (NYSE:NEO) to $11.00
Having a price of $8.07, NeoPharm Inc. (NYSE:NEO) traded -1.76% lower on the day. With the last close down -0.12% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. NeoPharm Inc. has recorded a 50-day average of $8.11 and a two hundred day average of $8.09. Volume of trade was down over the average, with 130,592 shares of NEO changing hands under the typical 318,055
With a total market value of $0, NeoPharm Inc. has with a one year low of $5.49 and a one year high of $9.54 .
A total of 6 analysts have released a research note on NeoPharm Inc.. Four analysts rating the company a strong buy, two analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $9.63.
More About NeoPharm Inc. (NYSE:NEO)
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.